J.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer

Executive Officer January 11, 2021 1Exhibit 99.1 J.P. MORGAN Healthcare Conference Prahlad Singh Chief Executive Officer January 11, 2021 1

SAFE HARBOR This presentation contains forward-looking statements which

are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and

end-markets, and plans concerning business development opportunities. Words such as believes, intends, anticipates, plans, expects, projects, forecasts, will and similar expressions, and references to guidance, are intended to identify

forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause

actual results to differ materially from the results described, implied or projected in any forward-looking statements. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking

statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any

intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. In addition to financial measures prepared in accordance with generally accepted accounting principles

(GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the "Investor Events" section

of our investor relations website at ir.perkinelmer.com. 2SAFE HARBOR This presentation contains forward-looking statements which are statements relating to future events. These statements include those relating to estimates and projections of

future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as believes, intends, anticipates,

plans, expects, projects, forecasts, will and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can

be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These

uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most

recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this

presentation. In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly

comparable GAAP measures is included in the embedded hyperlink and is available on the "Investor Events" section of our investor relations website at ir.perkinelmer.com. 2

WHAT YOU'LL HEAR TODAY Positioning Us for Future Success

Continued Progress against Our Strategic Foundation COVID-19 response validates our foundational efforts RECENT FOCUS VALUE CREATION FRAMEWORK PORTFOLIO Enhanced Diagnostics brand Add Meaningful TRANSFORMATION Scale bolsters existing

positions Maximize Growth Accelerators ORGANIZATIONAL ALIGNMENT Confidence in long-term Strengthen Core Right to Win value creation opportunities Operational STRATEGIC Excellence to Drive PRIORITIES Margin & Efficiency 3WHAT YOU'LL HEAR

TODAY Positioning Us for Future Success Continued Progress against Our Strategic Foundation COVID-19 response validates our foundational efforts RECENT FOCUS VALUE CREATION FRAMEWORK PORTFOLIO Enhanced Diagnostics brand Add

Meaningful TRANSFORMATION Scale bolsters existing positions Maximize Growth Accelerators ORGANIZATIONAL ALIGNMENT Confidence in long-term Strengthen Core Right to Win value creation opportunities Operational STRATEGIC Excellence to Drive PRIORITIES

Margin & Efficiency 3

PORTFOLIO TRANSFORMATION Positioned for more stable Attractive

>80% of 2020 revenue from END MARKETS MSD+ growth Diagnostics and Life Sciences Improved >70% of portfolio in consumables, Supporting more consistent PRODUCT MIX services, & software and linear revenue Increased 33% of

revenue in Revenue balanced equally across GEOGRAPHIC REACH higher growth emerging markets the globe Expanded into adjacencies, increasing Strengthened ~$2.5B deployed capital CAPABILITIES TAM to $70-75B over past five years* Reinforcing our

solid foundation for continued success * Does not include the potential Oxford Immunotec acquistion 4PORTFOLIO TRANSFORMATION Positioned for more stable Attractive >80% of 2020 revenue from END MARKETS MSD+ growth Diagnostics and Life

Sciences Improved >70% of portfolio in consumables, Supporting more consistent PRODUCT MIX services, & software and linear revenue Increased 33% of revenue in Revenue balanced equally across GEOGRAPHIC REACH higher growth

emerging markets the globe Expanded into adjacencies, increasing Strengthened ~$2.5B deployed capital CAPABILITIES TAM to $70-75B over past five years* Reinforcing our solid foundation for continued success * Does not include the potential

Oxford Immunotec acquistion 4

STRENGTHENED CAPABILITIES: TWO RECENT ACQUISITIONS IN ADJACENT MARKETS

Attractive END MARKETS ~$800M capital deployed in new adjacent markets growing HSD Improved PRODUCT MIX Closed December 23 Closing 1H21 Increased GEOGRAPHIC REACH $3B TAM >$1B TAM Gene Editing Latent TB Diagnostics

Strengthened CAPABILITIES PKI Synergies Creating value through automation expertise Increasing global channel reach 5STRENGTHENED CAPABILITIES: TWO RECENT ACQUISITIONS IN ADJACENT MARKETS Attractive END MARKETS ~$800M

capital deployed in new adjacent markets growing HSD Improved PRODUCT MIX Closed December 23 Closing 1H21 Increased GEOGRAPHIC REACH $3B TAM >$1B TAM Gene Editing Latent TB Diagnostics Strengthened CAPABILITIES PKI Synergies

Creating value through automation expertise Increasing global channel reach 5

ORGANIZATIONAL ALIGNMENT Unified R&D Positioned 2K+ One to Drive

Product Vitality & Decrease Time Person Global R&D R&D Team to Market Global Commercial Unified 6K+ Resources Localized to Go-to- the Customer across a Global Commercial Market Resources Broad Portfolio Centralized Operations 3K+ Global

to Leverage Global Operations Operations & Expertise and Scale Logistics Team 6ORGANIZATIONAL ALIGNMENT Unified R&D Positioned 2K+ One to Drive Product Vitality & Decrease Time Person Global R&D R&D Team to Market Global

Commercial Unified 6K+ Resources Localized to Go-to- the Customer across a Global Commercial Market Resources Broad Portfolio Centralized Operations 3K+ Global to Leverage Global Operations Operations & Expertise and Scale Logistics Team

PROGRESS ON OUR STRATEGIC PRIORITIES STRONG ENHANCED FOCUSED

TRANSFORMATIVE TALENT & CUSTOMER OPERATIONAL INNOVATION CULTURE EXPERIENCE EXCELLENCE Strong employee Achieved 3 FDA EUAs Unified and Improved quote-to- retention (~8% voluntary and 13 CE-marks for new

personalized account delivery by ~20% turnover) Dx product launches relationships with full solution selling ~70% employees ex-US Launched Total Quality Primed >75% of DAS and increased leadership Initiative to embed

product revenue for NPI New Commercial diversity to >50% systematic changes upgrades over next 12-36 Office supporting global months Launched new core sales More transparent and values Incorporating seamless

efficient order Modern digital and automation and digital execution Published new CSR virtual reality tools tools across the portfolio report 7PROGRESS ON OUR STRATEGIC PRIORITIES STRONG ENHANCED FOCUSED TRANSFORMATIVE TALENT &

CUSTOMER OPERATIONAL INNOVATION CULTURE EXPERIENCE EXCELLENCE Strong employee Achieved 3 FDA EUAs Unified and Improved quote-to- retention (~8% voluntary and 13 CE-marks for new personalized account delivery by

~20% turnover) Dx product launches relationships with full solution selling ~70% employees ex-US Launched Total Quality Primed >75% of DAS and increased leadership Initiative to embed product revenue for NPI

New Commercial diversity to >50% systematic changes upgrades over next 12-36 Office supporting global months Launched new core sales More transparent and values Incorporating seamless efficient order Modern

digital and automation and digital execution Published new CSR virtual reality tools tools across the portfolio report 7

PERKINELMER TODAY Diagnostics ~75% ~25% (Dx) Consumables, Services,

Software Instruments ~30% ~40% $3.8B Asia Americas 2020e revenue* ~30% Discovery & Europe Analytical Solutions (DAS) 2020 Performance Adj. Gross Adj. Op Org. Rev Adj. EPS + + + 29% 500 bps 1000 bps 90 % Margin Margin Growth Growth

* Based on preliminary 4Q20 results, Reconciliations of these non-GAAP items to GAAP are provided on our website and here (link) 8PERKINELMER TODAY Diagnostics ~75% ~25% (Dx) Consumables, Services, Software Instruments ~30% ~40% $3.8B Asia

Americas 2020e revenue* ~30% Discovery & Europe Analytical Solutions (DAS) 2020 Performance Adj. Gross Adj. Op Org. Rev Adj. EPS + + + 29% 500 bps 1000 bps 90 % Margin Margin Growth Growth * Based on preliminary 4Q20 results,

Reconciliations of these non-GAAP items to GAAP are provided on our website and here (link) 8

DRIVING VALUE CREATION ACROSS THE PORTFOLIO VALUE CREATION FRAMEWORK

SEGMENT DEEP DIVES: DIFFERENTIATED POSITIONS L-T OUTLOOK DISCOVERY AND DIAGNOSTICS ANALYTICAL SOLUTIONS Add Meaningful Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts Virtual Life Science Event Strengthen Core

Confidence in December 2020 Right to Win long-term value Enhanced Diagnostics creation brand bolsters existing opportunities to positions drive strong Operational shareholder Excellence to Drive returns L-T Growth Outlook L-T Growth Outlook Margin

& Efficiency +MSD +HSD Focus of Today's Discussion 9DRIVING VALUE CREATION ACROSS THE PORTFOLIO VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES: DIFFERENTIATED POSITIONS L-T OUTLOOK DISCOVERY AND DIAGNOSTICS ANALYTICAL SOLUTIONS Add Meaningful

Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts Virtual Life Science Event Strengthen Core Confidence in December 2020 Right to Win long-term value Enhanced Diagnostics creation brand bolsters existing

opportunities to positions drive strong Operational shareholder Excellence to Drive returns L-T Growth Outlook L-T Growth Outlook Margin & Efficiency +MSD +HSD Focus of Today's Discussion 9

TRANSFORMATIVE DIAGNOSTICS VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES:

DIFFERENTIATED POSITIONS L-T OUTLOOK DIAGNOSTICS DAS Add Meaningful 1 Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts Virtual Life Science Event Strengthen Core Confidence in December 2020 Right to Win

long-term value Enhanced Diagnostics creation brand bolsters existing opportunities to positions drive strong Operational shareholder Excellence to Drive returns L-T Growth Outlook L-T Growth Outlook Margin & Efficiency +MSD +HSD Focus of

Today's Discussion 10TRANSFORMATIVE DIAGNOSTICS VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES: DIFFERENTIATED POSITIONS L-T OUTLOOK DIAGNOSTICS DAS Add Meaningful 1 Scale COVID-19 response Maximize Growth validates our Accelerators foundational

efforts Virtual Life Science Event Strengthen Core Confidence in December 2020 Right to Win long-term value Enhanced Diagnostics creation brand bolsters existing opportunities to positions drive strong Operational shareholder Excellence to Drive

returns L-T Growth Outlook L-T Growth Outlook Margin & Efficiency +MSD +HSD Focus of Today's Discussion 10

MOST SENSITIVE SARS-COV-2 DETECTION ASSAY Scaling Molecular 25M+ $350M+

Tests Shipped 2020e Revenue Lowest Limit-of-Detection Available on the Market 90x better than industry average New Coronavirus Nucleic Acid Detection Kit Note: FDA SARS-CoV-2 Reference Panel Comparative Data (link) 11MOST SENSITIVE SARS-COV-2

DETECTION ASSAY Scaling Molecular 25M+ $350M+ Tests Shipped 2020e Revenue Lowest Limit-of-Detection Available on the Market 90x better than industry average New Coronavirus Nucleic Acid Detection Kit Note: FDA SARS-CoV-2 Reference Panel Comparative

BEST-IN-CLASS EXTRACTION PORTFOLIO DELIVERED AT SCALE Superior Global

Performance Scale Leading >1,000 sensitivity chemagic 360 best-in-class magnetic placements in 2020 bead yield Fully- ~75 million automated chemagic tests TM high-throughput chemagic 360 and chemagic kits sold in 2020 processing Automated DNA and

RNA Extraction 12BEST-IN-CLASS EXTRACTION PORTFOLIO DELIVERED AT SCALE Superior Global Performance Scale Leading >1,000 sensitivity chemagic 360 best-in-class magnetic placements in 2020 bead yield Fully- ~75 million automated chemagic tests TM

high-throughput chemagic 360 and chemagic kits sold in 2020 processing Automated DNA and RNA Extraction 12

DIFFERENTIATED SARS-COV-2 SEROLOGY SOLUTIONS Combines fully-automated

Leveraging newborn screening with Capabilities best-in-class antibody assay technology Easy-to-use sample collection Novel with dried blood spot cards enables point-of-care, Sample Type decentralized sample collection GSP /DELFIA platform

DBS-based test for SARS-CoV-2 IgG High Total SARS-CoV-2 Serology: Up to 5,000 Throughput samples per day $75M Revenue $50M Backlog (2020) (2021) 13DIFFERENTIATED SARS-COV-2 SEROLOGY SOLUTIONS Combines fully-automated Leveraging newborn screening

with Capabilities best-in-class antibody assay technology Easy-to-use sample collection Novel with dried blood spot cards enables point-of-care, Sample Type decentralized sample collection GSP /DELFIA platform DBS-based test for

SARS-CoV-2 IgG High Total SARS-CoV-2 Serology: Up to 5,000 Throughput samples per day $75M Revenue $50M Backlog (2020) (2021) 13

COMPLETE WORKFLOW SOLUTION ENABLED BY UNIFIED R&D TEAM Novel

Innovation End-to-end automated workstation to streamline testing workflows and eliminate errors Flexibility to scale to meet current COVID-19 and future infectious disease testing needs, with best-in-class throughput up to 10K samples / day

explorer Workstation for SARS-CoV-2 RT-PCR Modular system provides customized degrees of automation based on customer needs Workstations Placed/Ordered* >20 * since August 2020 launch (link) 14COMPLETE WORKFLOW SOLUTION ENABLED BY UNIFIED

R&D TEAM Novel Innovation End-to-end automated workstation to streamline testing workflows and eliminate errors Flexibility to scale to meet current COVID-19 and future infectious disease testing needs, with best-in-class throughput up to 10K

samples / day explorer Workstation for SARS-CoV-2 RT-PCR Modular system provides customized degrees of automation based on customer needs Workstations Placed/Ordered* >20 * since August 2020 launch (link) 14

RECORD PERFORMANCE REVENUE INSTALLED BASE BRAND Meaningful ~1,750

>$1B Diagnostics new instruments placed Brand Recognition 2020e COVID revenue across the portfolio 15RECORD PERFORMANCE REVENUE INSTALLED BASE BRAND Meaningful ~1,750 >$1B Diagnostics new instruments placed Brand Recognition 2020e COVID

revenue across the portfolio 15

DIAGNOSTICS DEEP DIVE VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES:

DIFFERENTIATED POSITIONS L-T OUTLOOK DIAGNOSTICS DAS Add Meaningful Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts Virtual Life Science Event Strengthen Core 2 Confidence in December 2020 Right to Win

long-term value Enhanced Diagnostics creation brand bolsters existing opportunities to positions drive strong Operational shareholder Excellence to Drive returns L-T Growth Outlook L-T Growth Outlook Margin & Efficiency +MSD +HSD Focus of

Today's Discussion 16DIAGNOSTICS DEEP DIVE VALUE CREATION FRAMEWORK SEGMENT DEEP DIVES: DIFFERENTIATED POSITIONS L-T OUTLOOK DIAGNOSTICS DAS Add Meaningful Scale COVID-19 response Maximize Growth validates our Accelerators foundational efforts

Virtual Life Science Event Strengthen Core 2 Confidence in December 2020 Right to Win long-term value Enhanced Diagnostics creation brand bolsters existing opportunities to positions drive strong Operational shareholder Excellence to Drive returns

L-T Growth Outlook L-T Growth Outlook Margin & Efficiency +MSD +HSD Focus of Today's Discussion 16

IMMUNODIAGNOSTICS AT A GLANCE Infectious Highlighted Autoimmune Allergy

Other Diseases Portfolio Capabilities & Differentiators #1 #3 Leading Expanded Autoimmune Allergy Emerging Virus Neurodegenerative Testing Testing Menu Testing HOW WE WIN ~$1.0B ~85% 2020e Revenue Recurring Revenue Extensive menu with

over Scientific Expertise 500 unique tests Serviceable $4.5B Addressable Market: Highly innovative global Innovative Culture ~50% R&D collaborations Europe ~20% ~30% Americas Precise detection Technology Asia capabilities for

emerging Leadership diseases 17IMMUNODIAGNOSTICS AT A GLANCE Infectious Highlighted Autoimmune Allergy Other Diseases Portfolio Capabilities & Differentiators #1 #3 Leading Expanded Autoimmune Allergy Emerging Virus Neurodegenerative Testing

Testing Menu Testing HOW WE WIN ~$1.0B ~85% 2020e Revenue Recurring Revenue Extensive menu with over Scientific Expertise 500 unique tests Serviceable $4.5B Addressable Market: Highly innovative global Innovative Culture ~50%

R&D collaborations Europe ~20% ~30% Americas Precise detection Technology Asia capabilities for emerging Leadership diseases 17

IMMUNODIAGNOSTICS VALUE CREATION FOCUS Strengthen Share gain

opportunities with random access Core Right to Win Automation instruments for any throughput Maximize Growth Accelerators SuperFlex (CE-IVD) Accentis Add Meaningful Scale Lower / Point of Care Higher Throughput 18IMMUNODIAGNOSTICS VALUE

CREATION FOCUS Strengthen Share gain opportunities with random access Core Right to Win Automation instruments for any throughput Maximize Growth Accelerators SuperFlex (CE-IVD) Accentis Add Meaningful Scale Lower / Point of Care Higher